<DOC>
	<DOCNO>NCT01832558</DOCNO>
	<brief_summary>In prospective single centre placebo-controlled trial ten week , 24 CKD II-III patient ( eGFR 30-89 ml/min per 1.73 m2 ) DM II randomize enalapril 20mg per day two week run-in phase . Thereafter , patient either receive eplerenone 25mg ( n=12 ) placebo ( n=12 ) eight week . Eplerenone increase 50mg close monitoring serum potassium level . Employing novel mass-spectrometry ( MS ) -based method , quantification 10 different Ang metabolite ( Ang I , Ang II , Ang 1-7 , Ang 1-9 , Ang 2-10 , Ang 1-5 , Ang 2-7 , Ang 3-7 , Ang 3-8 Ang 2-8 ) perform simultaneously blood serum ( run-in phase 10 week ) .</brief_summary>
	<brief_title>The EPOCH Study ( Eplerenone Top ACE Inhibition Chronic Kidney Disease Patients With Hypertension )</brief_title>
	<detailed_description />
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>CKD II III diabetes mellitus type 2 CKD define accord estimate glomerular filtration rate ( eGFR ) MDRD formula eGFR 30 89 ml/min albumin excretion rate &gt; 300 mg/24 hour ( UACR &gt; 300 mg/gram ) &gt; 200 mg/g already receive RAS blockade Patients hypertonic stage I II accord European guideline ( Chobanian et al . JAMA 2003 ) Age &lt; 18 year UACR &gt; 3500mg/g severe hypertension pregnancy unwilling inability sign inform consent coronary heart disease systolic blood pressure &lt; 130 mmHg additional RAS interfering drug ( ACEis , ARBs , direct renin inhibitor ) 25hydroxy vitamin D level 16.6±8.3 pg/ml 1,25dihydroxy vitamin D 33.1±15.5 pg/ml Intolerance eplerenon excipient : tablettcore : LactoseMonohydrat Mikrokristalline Cellulose ( E 460 ) Croscarmellosesodium ( E 468 ) Hypromellose ( E 464 ) Sodiumdodecylsulfat Talkum ( E 553b ) Magnesiumstearat ( E 470b ) filmcoat Opadry , yellow : Hypromellose ( E 464 ) Titandioxid ( E 171 ) Macrogol 400 Polysorbat 80 ( E 433 ) Yellow ironoxide ( E 172 ) Red ironoxide ( E 172 ) Patients Serumpotassium &gt; 5,0 mmol/l start treatment Patients severe renal insufficiency ( eGFR &lt; 30ml/min./1.73 m2 ) Patients severe liver insufficiency ( ChildPugh class C ) Patients take potassium save diuretic , potassium supplement strong CYP3A4inhibitors ( z . B. Itraconazol , Ketoconazol , Ritonavir , Nelfinavir , Clarithromycin , Telithromycin und Nefazodon )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>